Sal Trading, LLC Argenx Se Put Options Transaction History

Sal Trading, LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$434.22 - $551.9 $694,752 - $883,040	-1,600 Reduced 76.19%	500 $271,000
Q2 2024 Aug 15, 2024	SELL	$356.01 - $451.55 $6.44 Million - $8.17 Million	-18,100 Reduced 89.6%	2,100 $903,000
Q1 2024 May 07, 2024	SELL	$356.95 - $413.29 $464,035 - $537,277	-1,300 Reduced 6.05%	20,200 $7.95 Million
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $6.03 Million - $9.01 Million	17,800 Added 481.08%	21,500 $8.18 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $1.37 Million - $2.03 Million	3,700 New	3,700 $1.82 Million
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $559,790 - $772,332	-2,200 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $598,422 - $776,665	2,200 New	2,200 $770,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Sal Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Sal Trading, LLC with notifications on news.